Changes In Lung Cancer Research Articles

High performance exhaled breath biomarkers for diagnosis of lung cancer and potential biomarkers for classification of lung cancer

Exhaled breath analysis has emerged as a promising non-invasive method for diagnosing lung cancer (LC), whereas reliable biomarkers are lacking. Herein, a standardized and systematic study was presented for LC diagnosis, classification and metabolism exploration. To improve the reliability of biomarkers, a validation group was included, and quality control for breath sampling and analysis, comprehensive pollutants analysis, and strict biomarker screening were performed. The performance of exhaled breath biomarkers was shown to be excellent in diagnosing LC even in early stages (stage I and II) with surpassing 0.930 area under the receiver operating characteristic (ROC) curve (AUC), 90% of sensitivity and 88% of specificity both in the discovery and validation analyses. Meanwhile, in these two groups, diagnosing subtypes of LC attained AUCs over 0.930 and reached 1.00 in the two subtypes of adenocarcinomas. It is demonstrated that the metabolism changes in LC are possibly related to lipid oxidation, gut microbial, cytochrome P450 and glutathione S-transferase, and glutathione pathways change in LC progression. Overall, the reliable biomarkers contribute to the clinical application of breath analysis in screening LC patients as well as those in early stages.

Temporal Changes in Lung Cancer: A 10-year Study in a Chest Hospital

No prospective, wide-scale study on lung cancer (LC) exists in Turkey. We aimed to determine prospectively epidemiologic features, histologic types, stages and temporal changes in LC in the Aegean Region of Turkey. This is the first prospective and largest LC study in Turkey. A hospital-based study was conducted on LC cases diagnosed between 1994 and 2004 at a tertiary referral hospital for thoracic medicine and surgery in Izmir, Turkey. The study was divided into two 5-year periods to determine temporal changes. Of 13,344 patients with pathologically confirmed LC, 93.1% was male. The mean age was 61.35 +/- 0.08 (59.5% between 41-65). The majority (82.5%) were smokers or ex-smokers. There was a 13.87% general rise in smoking rate, predominantly in females. LC incidence increased by 38% from 1994-1999 (42%) to 2000-2004 (58%); the contributive increases were 35.5% in males, and 77.5% in females. Frequent types were squamous cell carcinoma (24.7%), small cell carcinoma (SCLC) (14.2%) and adenocarcinoma (13.2%). Adenocarcinoma in the younger group (<40), females or non-smokers, and squamous cell carcinoma in the older group, males or smokers were the leading types. Non-small cell lung carcinoma (NSCLC) was mostly diagnosed at stages IIIB (36.7%) and IV (37%) whereas SCLC at limited stage (59.1%). The majority of the LC patients are over 40 years old, current or ex-smokers, or with squamous cell carcinoma. There is a general rise in smoking rate with a female predominance. The most common type is squamous cell carcinoma in males, and adenocarcinoma in females. NSCLC is diagnosed more frequently at advanced stage but SCLC at limited stage.

Change in IgG1Fc N‐linked glycosylation in human lung cancer: Age‐ and sex‐related diagnostic potential

The interactions of IgG Fc region with Fc receptors are optimized by the tailoring of a single-conserved N-linked glycosylation site at Asn-297. Our previous study has demonstrated that the age-related Fc-glycosylation change is featured by sex specificity and that the Fc-glycosylation has the potential for disease discrimination. Here, we conducted a Fourier transform ion cyclotron resonance MS-based profiling study involving 410 control individuals and 259 lung cancer (LC) patients. As compared to healthy controls, the marked increase in IgG1 Fc-agalactosylation and decrease in galactosylation were observed in LC patients. The binary logistic regression in combination with the receiver operating characteristic curve was used to determine the diagnostic ability of IgG1 Fc-glycosylation. It was found that this diagnostic ability was both sex and age dependent. Additionally, the change in Fc-glycosylation upon many different physiological and pathological conditions was retrospectively discussed. The data furthered the understanding of the immune-associated change in human LC, and also might be useful in the future attempts for Fc-glycosylation-associated diagnostic evaluations and clinical assays.